Alemtuzumab 3-year data show durable effect on MS disability
Posted: Fri Oct 11, 2013 2:52 am
Latest data from the CARE-MS II extension study show that alemtuzumab (Lemtrada, Genzyme/Sanofi) has a durable effect on disability in multiple sclerosis (MS), with the mean Expanded Disability Status Scale (EDSS) score at 3 years still below that at baseline.<br><br>
These new data were presented in a poster at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) last week...... Read More - http://www.ms-uk.org/lemtrada
These new data were presented in a poster at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) last week...... Read More - http://www.ms-uk.org/lemtrada